Navigation Links
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
Date:10/27/2010

had received at least one prior therapy and five patients were treated in the first-line setting.(1)  This Part 2 expansion cohort study of patients with ALK-positive advanced NSCLC, independent of the number of previous chemotherapies, followed the completion of the dose-escalation study which enrolled 37 advanced cancer patients with various tumors, including NSCLC, colorectal, pancreatic and inflammatory myofibroblastic tumor (IMT) tumors.(8)

These data were previously presented at the 2010 American Society of Clinical Oncology Annual Meeting.(7)

About Crizotinib (PF-02341066)

Crizotinib (PF-02341066) is a first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,(3) and is representative of Pfizer's personalized medicine approach to cancer treatment.  By inhibiting ALK, crizotinib (PF-02341066) blocks signaling in a number of cell pathways that may be critical for the growth and survival of tumor cells.(4)  Crizotinib (PF-02341066) is also an inhibitor of c-MET (mesenchymal endothelial transition factor).(3)

About Non-Small Cell Lung Cancer

Lung cancer is one of the most common cancers worldwide.(9)  NSCLC accounts for about 85 percent of lung cancer cases and remains difficult to treat, particularly in the metastatic setting. Approximately 75 percent of NSCLC patients are diagnosed late with metastatic, or advanced, disease, where the five-year survival rate is only 6 percent.(10,11)  In addition, the current standard of care for advanced NSCLC demonstrates a response rate of only about 15 percent.(12)  Approximately 3-5 percent of NSCLC tumors are ALK-positive.(4)

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China and the parent of ... for the first quarter ended March 31, 2013 [1] ... Total net revenue, which consists of net revenues generated ...
(Date:5/21/2013)... LAVAL, Quebec , May 21, ... Inc. (NYSE: VRX ) ... of ten directors nominated at its ... The detailed results of the vote ... set out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert ...
(Date:5/21/2013)...   Regulus Therapeutics Inc . ( NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that ... Officer and Executive Vice President, Finance, will present a ... Conference on Wednesday, May 29, 2013 at 3:30 pm ... Boston Waterfront Hotel. The presentation will be ...
Breaking Medicine Technology:Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2
... N.J., April 7, 2008 QMed, Inc.,(Nasdaq: ... a two year operating,extension from the Centers for ... Care Demonstration (MCCD) project in Northern,California., In ... pilot project to test whether,providing coordinated care services ...
... 2008 SuperGen Inc.,(Nasdaq: SUPG ), a ... commercialization of therapies for solid tumors and,hematological malignancies, ... oral and poster presentations at the AACR Annual ... Diego, California., An oral presentation by Dr. ...
Cached Medicine Technology:QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS 2SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 2SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 3
(Date:5/21/2013)... Prostaglandin analogues (PGAs), drugs which lower intraocular pressure, are ... glaucoma, but their use is not without risks. PGAs ... in eye color and other side effects. Now a ... upper and lower eyelid drooping and other issues that ... PLOS ONE . , Researchers from the Massachusetts ...
(Date:5/21/2013)... Artisan Business Group is to ... Conference in Long Beach, California on May 30, ... alternative finance through EB-5 immigrant investors program. The ... economic information, and updates to project developers, regional ... EB-5 industry. , "Our goal is to ...
(Date:5/21/2013)... 21, 2013 The federal judge overseeing ... lawsuits in U.S. District Court, Northern District ... a request from Plaintiffs’ Counsel to conduct Ex Parte ... May 17th Order grants that request, and sets forth ... re: Wright Medical Technology, Inc., Conserve Hip Implant Products ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... (DoDSR), University of Cincinnati (UC) researchers have identified a ... could help with earlier diagnosis and intervention in those ... the first of its kind and led by UC,s ... by staff from Walter Reed National Military Medical Center ... in Orlando, Fla. , The DoDSR is a ...
Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2
... Hydroxycut products, consumers who have suffered injuries from using Hydroxycut are ... attorney to determine if he/she is eligible for compensation. Lawinfo provides ... ... San Diego, CA (PRWEB) May 26, 2009 -- For ...
... held consulting company, announced today its partnership ... automated software solutions. Veracord,s comprehensive IT expertise ... product delivery to quality software IT implementation ... clients in the Life Sciences industry a ...
... a Finalist in the 2009 American Business Awards for its Interactive ... ... May 26, 2009 -- The American Business Awards are the nation,s ... eligible to submit entries to the ABAs - public and private, ...
... People Save More Money into Health Savings Accounts - A Smart and Simple ... ... Healthy Rebates, Inc. today announced the launch of My HSA Rewards, a web ... to help save more money for health care. , , ,The program, ...
... (Aircraft),the UK medical devices company, today announces that ... market with the acquisition of,Morpheus Medical (Morpheus), the ... Morpheus is a leading developer of patient ... Morpheus, lead product, the IoC-View,is designed to measure ...
... and simple way to diagnose a serious problem facing ... Ph.D., M.P.H., MetroHealth System pediatrician, internist, and chief medical ... Medicine researcher and faculty member. Nearly 75% of ... in children and adolescents go undiagnosed. These troubling ...
Cached Medicine News:Health News:LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide 2Health News:Veracord and Parasoft Partner to Improve Compliance and Reduce Cost 2Health News:Veracord and Parasoft Partner to Improve Compliance and Reduce Cost 3Health News:iHealthSpot, Inc Named as Finalist in American Business Awards(sm) 7th Annual Stevie Awards will be Presented on June 22 in New York City 2Health News:iHealthSpot, Inc Named as Finalist in American Business Awards(sm) 7th Annual Stevie Awards will be Presented on June 22 in New York City 3Health News:Healthy Rebates, Inc. Announces the Launch of My HSA Rewards 2Health News:Aircraft Medical Enters Anaesthesia Monitoring Market With Acquisition of Morpheus Medical, S.L. 2Health News:Pediatrician creates easier way to identify kids' high BP 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: